Skip to main content
ADALTA LIMITED logo

ADALTA LIMITED — Investor Relations & Filings

Ticker · 1AD ISIN · AU0000001AD2 LEI · 254900XT3BQIT6GR6M94 ASX Professional, scientific and technical activities
Open in API
Filings indexed 726 across all filing types
Latest filing 2023-08-06 Investor Presentation
Country AU Australia
Listing ASX 1AD

About ADALTA LIMITED

https://adalta.com.au/

AdAlta Limited is a clinical-stage biotechnology company focused on the discovery and development of a new class of protein therapeutics called i-bodies. The company utilizes its proprietary i-body platform to engineer highly stable, small-format proteins that mimic the binding characteristics of shark antibodies. These i-bodies are designed to target complex disease-related proteins that are often inaccessible to traditional monoclonal antibodies. AdAlta's lead therapeutic candidate, AD-214, is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic conditions. The platform's versatility allows for the creation of diverse therapeutic leads across multiple disease areas, including inflammation and oncology, by leveraging the unique structural properties of the human protein scaffold-based i-body library.

Recent filings

Filing Released Lang Actions
Investor webinar - recent AD-214 progress 2 pages 356.4KB
Investor Presentation Classification · 90% confidence The document is an ASX announcement dated 7 August 2023 from AdAlta Limited. It invites investors to an upcoming investor update webinar regarding the progress of a clinical study (AD-214 Phase 1 extension study). The content focuses on an investor briefing invitation and company background information, with no financial statements, detailed financial data, or regulatory filings. The document is relatively short (4684 characters) and serves as an announcement of an event rather than a report or detailed financial disclosure. Therefore, it fits best as an Investor Presentation (IP) type, as it is a detailed presentation for investors focusing on company progress and strategy, albeit in webinar invitation form. The document is not a full report, earnings release, or regulatory filing, nor is it a report publication announcement. Confidence is high given the clear nature of the content and format.
2023-08-06 English
AD-214 returns to clinic 2 pages 410.5KB
Capital/Financing Update Classification · 90% confidence The document is an ASX announcement dated 4 August 2023 providing an update on the clinical study progress of AdAlta Limited's drug candidate AD-214. It discusses the dosing in a Phase I extension study, expected interim and full results, and ongoing discussions with potential partners. The content is an operational update on clinical trials and company progress rather than a financial report, earnings release, or regulatory filing. It does not contain financial statements, voting results, or management changes. The document is a company announcement about clinical development progress and partnership discussions, fitting best under Capital/Financing Update (CAP) as it relates to development progress that impacts company valuation and potential financing or partnerships. The document length is about 5951 characters, which is consistent with a detailed announcement but not a full report. Therefore, the most appropriate classification is CAP with high confidence.
2023-08-03 English
Change in substantial holding 3 pages 149.5KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 filed under the Corporations Act 2001, specifically a "Notice of change of interests of substantial holder." It details changes in voting power and relevant interests of a substantial shareholder group in AdAlta Limited, including dates and share counts. This type of filing is a notification of changes in major shareholdings, not a financial report, management announcement, or other categories. It matches the definition of Major Shareholding Notification (MRQ). The document length and content confirm it is the actual notification, not just an announcement or certification.
2023-07-20 English
Notification of cessation of securities - 1AD 4 pages 23.8KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Notification of cessation of +securities' and details the lapse of certain options (securities) due to conditions not being met. It provides specific information about the securities that have ceased, the number of securities, reasons for cessation, and the updated issued capital following these changes. The document is an announcement about changes in the company's issued securities, specifically the cessation of certain securities. It does not contain financial statements, management discussion, or detailed financial results. It is not a full report but an announcement related to capital changes. Therefore, the most appropriate classification is 'Share Issue/Capital Change' (SHA). The document length is 3632 characters, which is consistent with an announcement rather than a full report.
2023-07-13 English
Change in substantial holding 3 pages 159.2KB
Regulatory Filings Classification · 90% confidence The document text is extremely short (316 characters) and contains no meaningful textual content, only placeholders for omitted pictures and some nonsensical tabular data. There is no indication of any report, announcement, or regulatory filing content. Given the lack of substantive information, the document does not fit any specific filing category and defaults to the fallback category for miscellaneous filings.
2023-07-13 English
Quarterly Appendix 4C and Activities Report 13 pages 674.9KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 13 July 2023 titled 'Quarterly Activities Report – June Quarter 2023'. It provides a detailed overview of the company's operations, clinical trial progress, partnering activities, financial position, and corporate development for the quarter ending 30 June 2023. The content includes substantive financial data such as cash position, capital raised, and operational milestones. The document is comprehensive and exceeds 5,000 characters, indicating it is a full report rather than a brief announcement or summary. The nature of the report aligns with an Interim / Quarterly Report (IR) as it covers a period shorter than a full fiscal year and contains detailed financial and operational information. It is not a simple earnings release or a regulatory filing, nor is it an annual report or audit report. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q4 2023
2023-07-12 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.